Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial

The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI). This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and sev...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroinflammation 2016-06, Vol.13 (1), p.152-152, Article 152
Main Authors: Allison, David J, Thomas, Aysha, Beaudry, Kayleigh, Ditor, David S
Format: Article
Language:English
Subjects:
Adult
Aged
Antioxidants - administration & dosage
Care and treatment
Clinical trials
Complications and side effects
Diet, Carbohydrate-Restricted - methods
Diet, Protein-Restricted - methods
Female
Humans
Inflammation
Inflammation Mediators - antagonists & inhibitors
Inflammation Mediators - blood
Male
Middle Aged
Neuralgia - blood
Neuralgia - diagnosis
Neuralgia - diet therapy
Risk factors
Spinal cord injuries
Spinal Cord Injuries - blood
Spinal Cord Injuries - diagnosis
Spinal Cord Injuries - diet therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733
cites cdi_FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733
container_end_page 152
container_issue 1
container_start_page 152
container_title Journal of neuroinflammation
container_volume 13
creator Allison, David J
Thomas, Aysha
Beaudry, Kayleigh
Ditor, David S
description The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI). This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4. A significant group × time interaction was found for sensory pain scores (p 
doi_str_mv 10.1186/s12974-016-0625-4
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4912827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468880350</galeid><sourcerecordid>A468880350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733</originalsourceid><addsrcrecordid>eNptUk1rFTEUDaLY9ukPcCMBN26m5jszLoRSrAoFN3Ud7mQyr3lkkjGZKTx_vXm8WluRLJLcnHNy7-Eg9IaSc0pb9aFQ1mnREKoaophsxDN0SrVgDSOdeP7ofILOStkRwplU7CU6YZpTpXR7iu5uIG_d4uMW-zgGmCZYfIoYCga8ZAfL5OKCpzRA8Msejynj6NacZlhuvcUz-FiZuMw-QsA25aFed2vef6wCGeKQJv_LDdgGH72tkCV7CK_QixFCca_v9w36cfX55vJrc_39y7fLi-vGSkWW2rvmTjIOzAIlvVSDHDspiG0JEb2GUSkYBQdO1Ng7RZzTAH3fd7RWpOZ8gz4ddee1n9xg6ywZgpmznyDvTQJvnr5Ef2u26c6IjrK22rRB7-8Fcvq5urKYyRfrQoDo0loM1V3bdUpyWaHv_oHu0pqrKxVV-9WtUET9RW0hOFM9T_VfexA1F0K1bUu4JBV1_h9UXYObvE3Rjb7WnxDokWBzKiW78WFGSswhLOYYFlPDYg5hMaJy3j4254HxJx38NxdOuxY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1800784606</pqid></control><display><type>article</type><title>Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Allison, David J ; Thomas, Aysha ; Beaudry, Kayleigh ; Ditor, David S</creator><creatorcontrib>Allison, David J ; Thomas, Aysha ; Beaudry, Kayleigh ; Ditor, David S</creatorcontrib><description>The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI). This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4. A significant group × time interaction was found for sensory pain scores (p &lt; 0.01). A Mann-Whitney test revealed that the change scores (3-month baseline) were significantly different between groups for IFN-y (U = 13.0, p = 0.01), IL-1β (U = 14.0, p = 0.01), and IL-2 (U = 12.0, p = 0.01). A Friedman test revealed the treatment group had a significant reduction in IFN-y (x (2) = 8.67, p = 0.01), IL-1β (x (2) = 17.78, p &lt; 0.01), IL-6 (x (2) = 6.17, p &lt; 0.05), while the control group showed no significant change in any inflammatory mediator. A stepwise backward elimination multiple regression analysis showed that the change in sensory neuropathic pain was a function of the change in the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (R = 0.689, R (2) = 0.474). Overall, the results of the study demonstrate the efficacy of targeting inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism relating to the reduction in proinflammatory cytokines and PGE2. ClinicalTrials.gov, NCT02099890.</description><identifier>ISSN: 1742-2094</identifier><identifier>EISSN: 1742-2094</identifier><identifier>DOI: 10.1186/s12974-016-0625-4</identifier><identifier>PMID: 27316678</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Antioxidants - administration &amp; dosage ; Care and treatment ; Clinical trials ; Complications and side effects ; Diet, Carbohydrate-Restricted - methods ; Diet, Protein-Restricted - methods ; Female ; Humans ; Inflammation ; Inflammation Mediators - antagonists &amp; inhibitors ; Inflammation Mediators - blood ; Male ; Middle Aged ; Neuralgia - blood ; Neuralgia - diagnosis ; Neuralgia - diet therapy ; Risk factors ; Spinal cord injuries ; Spinal Cord Injuries - blood ; Spinal Cord Injuries - diagnosis ; Spinal Cord Injuries - diet therapy ; Treatment Outcome</subject><ispartof>Journal of neuroinflammation, 2016-06, Vol.13 (1), p.152-152, Article 152</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733</citedby><cites>FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912827/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1800784606?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27316678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allison, David J</creatorcontrib><creatorcontrib>Thomas, Aysha</creatorcontrib><creatorcontrib>Beaudry, Kayleigh</creatorcontrib><creatorcontrib>Ditor, David S</creatorcontrib><title>Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial</title><title>Journal of neuroinflammation</title><addtitle>J Neuroinflammation</addtitle><description>The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI). This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4. A significant group × time interaction was found for sensory pain scores (p &lt; 0.01). A Mann-Whitney test revealed that the change scores (3-month baseline) were significantly different between groups for IFN-y (U = 13.0, p = 0.01), IL-1β (U = 14.0, p = 0.01), and IL-2 (U = 12.0, p = 0.01). A Friedman test revealed the treatment group had a significant reduction in IFN-y (x (2) = 8.67, p = 0.01), IL-1β (x (2) = 17.78, p &lt; 0.01), IL-6 (x (2) = 6.17, p &lt; 0.05), while the control group showed no significant change in any inflammatory mediator. A stepwise backward elimination multiple regression analysis showed that the change in sensory neuropathic pain was a function of the change in the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (R = 0.689, R (2) = 0.474). Overall, the results of the study demonstrate the efficacy of targeting inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism relating to the reduction in proinflammatory cytokines and PGE2. ClinicalTrials.gov, NCT02099890.</description><subject>Adult</subject><subject>Aged</subject><subject>Antioxidants - administration &amp; dosage</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Diet, Carbohydrate-Restricted - methods</subject><subject>Diet, Protein-Restricted - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation Mediators - antagonists &amp; inhibitors</subject><subject>Inflammation Mediators - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuralgia - blood</subject><subject>Neuralgia - diagnosis</subject><subject>Neuralgia - diet therapy</subject><subject>Risk factors</subject><subject>Spinal cord injuries</subject><subject>Spinal Cord Injuries - blood</subject><subject>Spinal Cord Injuries - diagnosis</subject><subject>Spinal Cord Injuries - diet therapy</subject><subject>Treatment Outcome</subject><issn>1742-2094</issn><issn>1742-2094</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptUk1rFTEUDaLY9ukPcCMBN26m5jszLoRSrAoFN3Ud7mQyr3lkkjGZKTx_vXm8WluRLJLcnHNy7-Eg9IaSc0pb9aFQ1mnREKoaophsxDN0SrVgDSOdeP7ofILOStkRwplU7CU6YZpTpXR7iu5uIG_d4uMW-zgGmCZYfIoYCga8ZAfL5OKCpzRA8Msejynj6NacZlhuvcUz-FiZuMw-QsA25aFed2vef6wCGeKQJv_LDdgGH72tkCV7CK_QixFCca_v9w36cfX55vJrc_39y7fLi-vGSkWW2rvmTjIOzAIlvVSDHDspiG0JEb2GUSkYBQdO1Ng7RZzTAH3fd7RWpOZ8gz4ddee1n9xg6ywZgpmznyDvTQJvnr5Ef2u26c6IjrK22rRB7-8Fcvq5urKYyRfrQoDo0loM1V3bdUpyWaHv_oHu0pqrKxVV-9WtUET9RW0hOFM9T_VfexA1F0K1bUu4JBV1_h9UXYObvE3Rjb7WnxDokWBzKiW78WFGSswhLOYYFlPDYg5hMaJy3j4254HxJx38NxdOuxY</recordid><startdate>20160617</startdate><enddate>20160617</enddate><creator>Allison, David J</creator><creator>Thomas, Aysha</creator><creator>Beaudry, Kayleigh</creator><creator>Ditor, David S</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160617</creationdate><title>Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial</title><author>Allison, David J ; Thomas, Aysha ; Beaudry, Kayleigh ; Ditor, David S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antioxidants - administration &amp; dosage</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Diet, Carbohydrate-Restricted - methods</topic><topic>Diet, Protein-Restricted - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation Mediators - antagonists &amp; inhibitors</topic><topic>Inflammation Mediators - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuralgia - blood</topic><topic>Neuralgia - diagnosis</topic><topic>Neuralgia - diet therapy</topic><topic>Risk factors</topic><topic>Spinal cord injuries</topic><topic>Spinal Cord Injuries - blood</topic><topic>Spinal Cord Injuries - diagnosis</topic><topic>Spinal Cord Injuries - diet therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allison, David J</creatorcontrib><creatorcontrib>Thomas, Aysha</creatorcontrib><creatorcontrib>Beaudry, Kayleigh</creatorcontrib><creatorcontrib>Ditor, David S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuroinflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allison, David J</au><au>Thomas, Aysha</au><au>Beaudry, Kayleigh</au><au>Ditor, David S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial</atitle><jtitle>Journal of neuroinflammation</jtitle><addtitle>J Neuroinflammation</addtitle><date>2016-06-17</date><risdate>2016</risdate><volume>13</volume><issue>1</issue><spage>152</spage><epage>152</epage><pages>152-152</pages><artnum>152</artnum><issn>1742-2094</issn><eissn>1742-2094</eissn><abstract>The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI). This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4. A significant group × time interaction was found for sensory pain scores (p &lt; 0.01). A Mann-Whitney test revealed that the change scores (3-month baseline) were significantly different between groups for IFN-y (U = 13.0, p = 0.01), IL-1β (U = 14.0, p = 0.01), and IL-2 (U = 12.0, p = 0.01). A Friedman test revealed the treatment group had a significant reduction in IFN-y (x (2) = 8.67, p = 0.01), IL-1β (x (2) = 17.78, p &lt; 0.01), IL-6 (x (2) = 6.17, p &lt; 0.05), while the control group showed no significant change in any inflammatory mediator. A stepwise backward elimination multiple regression analysis showed that the change in sensory neuropathic pain was a function of the change in the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (R = 0.689, R (2) = 0.474). Overall, the results of the study demonstrate the efficacy of targeting inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism relating to the reduction in proinflammatory cytokines and PGE2. ClinicalTrials.gov, NCT02099890.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27316678</pmid><doi>10.1186/s12974-016-0625-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-2094
ispartof Journal of neuroinflammation, 2016-06, Vol.13 (1), p.152-152, Article 152
issn 1742-2094
1742-2094
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4912827
source Publicly Available Content Database; PubMed Central
subjects Adult
Aged
Antioxidants - administration & dosage
Care and treatment
Clinical trials
Complications and side effects
Diet, Carbohydrate-Restricted - methods
Diet, Protein-Restricted - methods
Female
Humans
Inflammation
Inflammation Mediators - antagonists & inhibitors
Inflammation Mediators - blood
Male
Middle Aged
Neuralgia - blood
Neuralgia - diagnosis
Neuralgia - diet therapy
Risk factors
Spinal cord injuries
Spinal Cord Injuries - blood
Spinal Cord Injuries - diagnosis
Spinal Cord Injuries - diet therapy
Treatment Outcome
title Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A20%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20inflammation%20as%20a%20treatment%20modality%20for%20neuropathic%20pain%20in%20spinal%20cord%20injury:%20a%20randomized%20clinical%20trial&rft.jtitle=Journal%20of%20neuroinflammation&rft.au=Allison,%20David%20J&rft.date=2016-06-17&rft.volume=13&rft.issue=1&rft.spage=152&rft.epage=152&rft.pages=152-152&rft.artnum=152&rft.issn=1742-2094&rft.eissn=1742-2094&rft_id=info:doi/10.1186/s12974-016-0625-4&rft_dat=%3Cgale_pubme%3EA468880350%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c560t-2073e523a2ca10b56d5f9540c8004b7af66af43a306fbe60ee7aabbb913065733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1800784606&rft_id=info:pmid/27316678&rft_galeid=A468880350&rfr_iscdi=true